Champions Oncology
CSBR
34 hedge funds and large institutions have $51.4M invested in Champions Oncology in 2025 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 1 closing their positions.
2,050% more call options, than puts
Call options by funds: $387K | Put options by funds: $18K
900% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 1
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
36% more funds holding
Funds holding: 25 → 34 (+9)
1.41% more ownership
Funds ownership: 41.38% → 42.79% (+1.4%)
5% more capital invested
Capital invested by funds: $49M → $51.4M (+$2.35M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.17M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
+$810K |
| 3 |
Millennium Management
New York
|
+$564K |
| 4 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
+$264K |
| 5 |
Goldman Sachs
New York
|
+$234K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Tocqueville Asset Management
New York
|
-$2.12M |
| 2 |
VF
Virtu Financial
New York
|
-$95K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$42K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$11.5K |
| 5 |
BlackRock
New York
|
-$4.47K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $66K | +$77.3K | +7,626 | New |
|
27
Citigroup
New York
| $42.7K | +$49.8K | +4,915 | New |
|
28
UBS Group
Zurich,
Switzerland
| $4.59K | +$5.36K | +529 | New |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| $4.35K | -$11.5K | -1,139 | -69% |
|
30
Osaic Holdings
Scottsdale,
Arizona
| $868 | – | – | – |
|
|
SS
31
SBI Securities
Tokyo,
Japan
| $139 | +$122 | +12 | +300% |
|
32
JP Morgan Chase
New York
| $95 | – | – | – |
|
|
GC
33
Garde Capital
Seattle,
Washington
| $9 | +$10 | +1 | New |
|
|
VF
34
Virtu Financial
New York
| – | -$95K | -11,051 | Closed |
|
CSBR Hedge Fund Activity: Q1 2025 in Review
34 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Champions Oncology (CSBR) for Q1 2025, worth a combined $51.4M — up 4.8% from $49M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CSBR positions and 1 closed out — a net gain of 9 holders — while 10 added to existing stakes and 6 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $1.17M. The largest seller was Tocqueville Asset Management, cutting an estimated $2.12M.
- 34 institutional investors held Champions Oncology (CSBR) as of Q1 2025, up from 25 in Q4 2024.
- Funds reported $51.4M of Champions Oncology stock for Q1 2025, up 4.8% quarter-over-quarter.
- 10 funds opened new Champions Oncology positions in Q1 2025 and 1 closed out, a net change of +9 holders.
- The largest Champions Oncology buyer in Q1 2025 was Susquehanna International Group, an estimated $1.17M added.
- The largest Champions Oncology seller in Q1 2025 was Tocqueville Asset Management, an estimated $2.12M sold.
Based on aggregated 13F filings for Q1 2025.